Chemotherapy-induced Alopecia Treatment Device Market Size, Share & Trends Analysis Report By Product (Manual Cooling Systems, Automated Cooling Systems), By Sales Modality, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Chemotherapy-induced Alopecia Treatment Device Market Size, Share & Trends Analysis Report By Product (Manual Cooling Systems, Automated Cooling Systems), By Sales Modality, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Chemotherapy-induced Alopecia Treatment Device Market Growth & Trends

The global chemotherapy induced alopecia treatment device market size is anticipated to reach USD 174.7 million by 2030 and is projected to grow at a CAGR of 14.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving the market are increasing chemotherapy adoption, technological advancements, growing awareness & adoption, and government initiatives. In 2024, the American Cancer Society forecasts around 67,880 new cases of uterine cancer in the United States, with approximately 13,250 women expected to die from the disease. This significant number of cases highlights an ongoing need for effective treatment options, including chemotherapy-induced alopecia (CIA) treatment devices. As many of these patients undergo chemotherapy, there will be an increased demand for solutions that address hair loss, underscoring the importance of CIA treatment devices in supporting women through their cancer treatment journey

Advancements in chemotherapy-induced alopecia (CIA) treatment devices are driving the market growth. According to NCBI article published in March 2024, Cold capping, a non-pharmacologic approach to reducing chemotherapy-induced alopecia (CIA), is gaining recognition for its potential to preserve hair during treatment. A study reviewing the real-world effectiveness and tolerability of a manual cold capping system across diverse patient demographics found that 95% of the 100 patients who initiated cold capping completed the process. The median hair retention was reported at 75%, with 92.1% of patients achieving favorable results, defined as retaining 50% or more of their hair.

Chemotherapy-induced Alopecia Treatment Device Market Report Highlights

• The manual cooling systems segment led the market with the largest revenue share of 52.7% in 2023, due to ongoing product advancements, growing initiatives by key companies, and increasing cancer prevalence
• Based on sales modality, the rental sales segment led the market with the largest revenue share of 80.9% in 2023. Growing patient awareness of scalp cooling systems has increased demand for rental options. As more individuals seek to mitigate chemotherapy-induced hair loss, healthcare providers are expanding their services to include rental programs, enhancing accessibility
• Based on indication, the breast cancer segment led the market with the largest revenue share of 66.9% in 2023. Rising incidence of breast cancer, technological advancement, and growing awareness drive the market growth
• Based on end use, the hospital segment led the market with the largest revenue share at 44.8% in 2023. Hospitals are integrating these CIA devices into their oncology departments to offer patients a proven method for mitigating chemotherapy-related hair loss
• North America dominated the market with the largest revenue share of 52.8% in 2023. Rising cancer cases, product launches, regulatory approvals, and advanced healthcare infrastructure drive North America's demand for CIA treatment devices

Please note The report will be delivered in 2-3 business days upon order notification.